ndd Medical Technologies Reports New Inline Filters Offer Additional Protection Against COVID-19 During Lung Function Tests

ndd Medical Technologies (ndd), a leading provider of diagnostic technology enabling healthcare professionals the early detection of COPD and other chronic lung diseases, has introduced new single patient-use, inline filters for its lung function testing devices, in response to the global COVID-19 pandemic.

Ensuring an added level of safety, the new filters can be used with ndd’s revolutionary, and highly portable EasyOne® spirometry range, including the EasyOne Air, EasyOne Pro, and EasyOne Pro LAB. EasyOne spirometers are popular among pulmonologists and medical researchers as they are of the most sensitive devices available, delivering reliable, real-time lung function results and diagnosis of chronic lung diseases, even at the point of care.

COVID-19 has had a massive impact on global healthcare systems, and the safety of both patients and healthcare professionals during lung function testing is paramount.1 In addition, as the SARSCoV2 virus is known to affect the lungs, there is growing research into the effects of COVID-19 on lung function post-infection.2

The EasyOne product line was originally designed with a strong focus on infection control with easy-to-wipe surfaces, single-use parts for anything that comes into contact with a patient’s breath, and ndd’s unique spirette and flow tube design which protects the flow sensor from cross-contamination. Now, when performing spirometry and testing of the diffusing capacity of the lungs for carbon monoxide (DLCO tests), the new EasyOne inline, single patient-use filters provide “double protection” for technicians and patients by keeping the ambient environment clean, without significantly affecting the EasyOne’s sensitivity.3

Leading pulmonologists and medical researchers around the world use ndd’s lung function testing products due to portability, which means they can easily be used in point of care settings, and because they are of the most sensitive devices available. ndd’s rigorous sensitivity tests have shown that the new inline filters do not significantly affect this sensitivity and show comparable results in 24 waveform testing, (as required by ATS/ERS) and pass testing requirements3. World-renowned medical research organizations—such as Johns Hopkins University, University Hospital Zurich and University of Cape Town—are partnering with ndd to assess the long-term lung damage caused by SARSCoV2.

Dr Trishul Siddharthan, Assistant Professor of Pulmonary and Critical Care Medicine at Johns Hopkins University, commented, “There is a lot of research underway to investigate the long-term effects of COVID-19. Our research group has been partnering with ndd thanks to the reliability of these spirometers in global settings and the ease of cleaning these devices during the pandemic to ensure safety.”

Prof. Friedrich Thienemann, General Medicine & Global Health research group, University of Cape Town and University Hospital Zurich, also noted, “In order to measure lung functions in resource-constraint settings like South African townships, one needs a device that is portable, point-of-care, easy-to-use, low-maintenance, and reliable without complicated calibration. EasyOne Pro LAB is that device.”

Incorporating ndd’s patented TrueFlowTM ultrasound technology, the EasyOne translates airflow into ultrasound signals which are measured by the sensors, so the patient’s breath does not come into contact with the sensors. This helps to prevent contamination and minimizes the cleaning required for safe use, while enabling a lifetime of calibration-free accuracy for flow and volume measurements.

Georg Harnoncourt, ndd Medical’s CEO, commented: “At ndd we have always designed our lung function testing products with safety in mind, so since the onset of the COVID-19 pandemic, we have worked tirelessly to develop additional infection control measures to protect both technicians and patients. Our EasyOne spirometers already offer superior infection control as everything that comes into contact with a person’s breath is replaced after use. In addition, our new inline filters have been carefully designed and tested so that, in combination with this superior infection control design, you can continue critical lung function testing during the COVID-19 pandemic as safely as possible.”


References

  1. Hull J, Lloyd J, Cooper B. Lung function testing in the COVID-19 endemic. The Lancet Respiratory Medicine. 2020;20.
  2. Mo X, Jian W, Su Z, Chen M, Peng H, Peng P et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. European Respiratory Journal. 2020;55(6):2001217.
  3. ndd Medical. Internal data on file. 2020.
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Research liquids are the key accessories for various research processes, and Lotilabs offers the best quality research liquids.
Asep Medical Holdings received confirmation from its attorneys of its US Patent Application No. 16/279788, which has been subsequently validated in the US, representing 332 million people. This patent is in addition to the successful European and Australian patents awarded to the Company in November of 2022, which represent approximately 400 million people.
“By harnessing the power of AI models and algorithms, with our unique data and experiments, we're unlocking scientific discoveries with incredible speed and generating insights at an unprecedented scale,” said Aviv Regev, EVP and head of Genentech Research and Early Development (gRED). “Bringing science and technology together has always been a foundation of biomedical breakthroughs at Genentech. We are thrilled to join forces with NVIDIA to further optimize our drug discovery and development to deliver treatments that transform people’s lives.”
"We've all had horrible teachers," recalls Jason Williams. Williams is Assistant Director of Diversity and Research Readiness at the Cold Spring Harbor Laboratory (CSHL) DNA Learning Center. "There have been efforts to improve science education at the undergraduate level for decades. But there's basically no effort to improve education once you've graduated. It's just assumed you'll somehow keep up."
"The assumption that we each have a single genome turns out to be off by a trillion-fold," said Geoffrey von Maltzahn, Ph.D., Co-Founder and Chief Executive Officer of Quotient Therapeutics and General Partner, Flagship Pioneering. "All cells accumulate random genetic changes in their DNA, resulting in trillions of unique genomes in the body. Some genetic changes make a cell resistant or vulnerable to disease, while others can cause disease. We started Quotient to study the natural genetics library inside every tissue, discover gene variants that are beneficial, neutral, or disease-causing, and to harness that knowledge to develop the medicines of tomorrow."

By using this website you agree to accept Medical Device News Magazine Privacy Policy